THMO

ThermoGenesis Holdings, Inc.
CAPPED RATING

Cesca Therapeutics Inc is engaged in the development and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

ThermoGenesis Holdings, Inc. (THMO) is rated C- (2.1/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 6.4%
Gross Margin 43.9%
Price Return 3M 0.0%
Price Return 12M 0.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -190.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-07-29 C+ (2.5) C (2.3) C- (1.9) C (2.2) D+ (1.5) C- (2.1)
2024-03-31 C+ (2.5) C (2.5) C (2.2) C- (2.1) D+ (1.5) C (2.2)
2023-09-30 C+ (2.5) C (2.3) D (1.4) C (2.3) D (1.5) C- (2.0)
2023-06-30 C+ (2.5) D (1.3) C- (2.0) C (2.3) D (1.5) C- (1.9)
2023-03-31 C+ (2.5) C- (1.9) C (2.3) C (2.3) D (1.5) C- (2.1)
Page 1 of 3